Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development

Area of Science:

• Vaccinology
• Virology
• Immunology
• Sexual and Reproductive Health

Background:

• Herpes simplex virus type 2 (HSV-2) infection causes significant global disease, including genital ulcers and neonatal herpes.
• HSV-2 infection is a primary risk factor for HIV-1 acquisition, increasing susceptibility severalfold.
• HSV-2 establishes inflammation in the genital mucosa, attracting target cells for HIV entry.

Purpose of the Study:

• To review the biological interactions between HSV-2 and HIV-1.
• To examine HSV-2 vaccine development within the context of HIV risk.
• To discuss implications and future research needs for HSV vaccine development.

Main Methods:

• Literature review of biologic interactions between HSV-2 and HIV-1.
• Analysis of HSV-2 vaccine development strategies (prophylactic and therapeutic).
• Consideration of potential impacts of HSV-2 vaccines on HIV risk.

Main Results:

• HSV-2 infection creates mucosal ulcerations and recruits immune cells (dendritic cells, CD4+ T cells) that are susceptible to HIV.
• Prophylactic and therapeutic HSV-2 vaccines aim to prevent or modify infection, potentially reducing HSV-associated inflammation and HIV risk.
• The effect of an HSV-2 vaccine on HIV risk may be complex, depending on its mechanism and the immune response generated.

Conclusions:

• An effective HSV-2 vaccine holds potential for reducing HSV-2 disease burden and decreasing HIV transmission.
• Careful consideration of vaccine-induced immune responses in the genital mucosa is crucial for optimizing HIV risk reduction.
• Further research is needed to understand and harness the dual potential of HSV-2 vaccines for both HSV-2 and HIV prevention.